28923-53-7

Upstream product

• 100-39-0 benzyl bromide 
• 3004-42-0 2-Mercapto-5-phenyl-1,3,4-oxadiazole 
• 613-94-5 benzoic acid hydrazide 
• 75-15-0 carbon disulfide 
• 100-44-7 benzyl chloride 
• 93-58-3 benzoic acid methyl ester 
• 65-85-0 benzoic acid 

Downstream Products

• 3012-37-1 benzyl thiocyanate 
• 55-21-0 benzamide 
• 100-47-0 benzonitrile 
• 103-29-7 1,1'-(1,2-ethanediyl)bisbenzene 
• 62-53-3 aniline 
• 13906-09-7 2-mercapto-3H-quinazolin-4-one 
• 1258933-13-9 4-(5-phenyl-1,3,4-oxadiazol-2-yl)-1,4-diazatricyclo[4.3.1.1(3,8)]undecane 
• 677723-97-6 2-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-5-phenyl-1,3,4-oxadiazole 

Relevant academic research and scientific papers

COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS

Disclosed are compounds that can be used for treating tuberculosis.

Structure-based optimization of oxadiazole-based GSK-3 inhibitors

Inhibition of glycogen synthase kinase-3 (GSK-3) induces neuroprotective effects, e.g. decreases β-amyloid production and reduces tau hyperphosphorylation, which are both associated with Alzheimer's disease (AD). The two isoforms of GSK-3 in mammalians are GSK-3α and β, which share 98% homology in their catalytic domains. We investigated GSK-3 inhibitors based on 2 different scaffolds in order to elucidate the demands of the ATP-binding pocket [1]. Particularly, the oxadiazole scaffold provided potent and selective GSK-3 inhibitors. For example, the most potent inhibitor of the present series, the acetamide 26d, is characterized by an IC50 of 2 nM for GSK-3α and 17 nM for GSK-3β. In addition, the benzodioxane 8g showed up to 27-fold selectivity for GSK-3α over GSK-3β, with an IC 50 of 35 nM for GSK-3α. Two GSK-3 inhibitors were further profiled for efficacy and toxicity in the wild-type (wt) zebrafish embryo assay to evaluate simultaneously permeability and safety.

One-pot synthesis of 2-Alkylthio-1,3,4-oxadiazole and Bis-(1,3,4- oxadiazole-2-yl)thio alkyl derivatives from acid hydrazides and CS2

An efficient and one-pot method for synthesis of 2-alkylthio-1,3,4- oxadiazole derivatives in mild conditions is described. Some novel derivatives such as bis-1,3,4-oxadiazole analogs are also synthesized.

Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents

A series of 2-(benzylthio)-5-aryloxadiazole derivatives have been designed and synthesized, and their biological activities are also evaluated for EGFR inhibitory activity. Fourteen compounds among the twenty compounds are reported for the first time. Their chemical structures are characterized by 1H NMR, MS, and elemental analysis. Anti-proliferative and EGFR inhibition assay results have demonstrated that compound 3e shows the most potent biological activity (IC50 = 1.09 μM for MCF-7 and IC50 = 1.51 μM for EGFR). Docking simulation has been performed to position compound 3e into the EGFR active site to determine the probable binding model, with an estimated binding free energy value of -10.7 kcal/mol. Compound 3e with potent inhibitory activity in tumor growth inhibition may be a promising anti-tumor leading compound for the further research.

A novel one-pot synthesis of 2-alkylthio-1,3,4-oxadiazoles in water

A facile and one-pot protocol for the synthesis of 2-alkylthio-1,3,4- oxadiazoles is reported. This green method relies on the reaction of acid hydrazides with CS2 and an alkyl halide. The reaction is carried out under mild and environmentally

DIAZAHOMOADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF

The invention relates to compounds that are diazahomoadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.

NOVEL DIAZABICYCLIC ARYL DERIVATIVES AND THEIR MEDICAL USE

This invention relates to novel diazabicyclic aryl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compoun

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE

This invention relates to novel 1,4-diazabicycloalkane derivatives of formula (I): any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, and their use in the manufacture of